Centessa Pharmaceuticals plc
CNTANASDAQHealthcare● Active
$39.67
+$0.05(+0.13%)
Market Cap$6.1B
P/E Ratio—
52W High$40.26
52W Low$10.95
Centessa Pharmaceuticals plc (CNTA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CNTA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $15.00M | $0.00M | $6.85M | $0.00M | $0.00M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $15.00M | $0.00M | $6.85M | $0.00M | $0.00M |
| Gross Margin %(computed) | 100.00% | — | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $172.22M | $150.24M | $124.41M | $155.08M | $96.32M |
| G&A Expenses | $50.47M | $50.81M | $53.73M | $55.20M | $43.01M |
| Total Operating Expenses | $222.69M | $201.06M | $178.14M | $212.26M | $374.87M |
| Operating Income | ($207.69M) | ($201.06M) | ($171.28M) | ($212.26M) | ($374.87M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $20.53M | $14.02M | $10.48M | $0.24M | $0.00M |
| Interest Expense | $11.46M | $10.09M | $9.91M | $7.28M | $2.55M |
| Income Before Tax | ($195.71M) | ($232.91M) | ($176.14M) | ($216.95M) | ($381.79M) |
| Income Tax Expense | $1.82M | $2.84M | ($25.06M) | ($0.75M) | $0.11M |
| Net Income | ($197.53M) | ($235.76M) | ($151.09M) | ($216.21M) | ($381.90M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.46 | $-2.06 | $-1.57 | $-2.31 | $-4.24 |
| Wtd Avg Shares | 135.72M | 114.47M | 96.18M | 93.40M | 89.99M |
| EBITDA | ($207.69M) | ($221.88M) | ($165.43M) | ($209.55M) | ($139.30M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Centessa Pharmaceuticals plc data
About Centessa Pharmaceuticals plc (CNTA) Income Statement
Centessa Pharmaceuticals plc (CNTA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CNTA reported revenue of $0.01B, gross profit of $0.01B (gross margin 100.00%), and net income of ($0.20B) — a net profit margin of -1316.88%.
Frequently asked questions
CNTA · 4 questionsCentessa Pharmaceuticals plc (CNTA) reported revenue of $0.01B for 2025, up —% year-over-year.
CNTA revenueCNTA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08